SCHEMBL9230440

SCHEMBL9230440

Cc1cc(O)c(C(C)(C)C)cc1CCc1cc(C(C)(C)C)c(O)cc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 6/20 0.56
ALDH1A1 P00352 6/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
CYP1A2 P05177 3/20 0.56
KDM4E B2RXH2 2/20 0.56
MAPT P10636 2/20 0.56
ATP2A2 P16615 1/20 0.56
ATP2A3 Q93084 1/20 0.56
HIF1A Q16665 5/20 0.55
TP53 P04637 4/20 0.55
CYP3A4 P08684 3/20 0.55
TSHR P16473 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
MAPK1 P28482 2/20 0.55
CYP2C9 P11712 7/20 0.50
CYP2C19 P33261 6/20 0.50
CYP2D6 P10635 3/20 0.50
HSD17B10 Q99714 3/20 0.43
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30471645 0.92 ALOX15 (0.52) ALOX15ALDH1A1SMN1; SMN2CYP1A2KDM4E
SCHEMBL2163484 0.92 ALOX15 (0.52) ALOX15ALDH1A1SMN1; SMN2CYP1A2KDM4E
SCHEMBL5073267 0.92 ALOX15 (0.52) ALOX15ALDH1A1SMN1; SMN2CYP1A2KDM4E
SCHEMBL6537028 0.90 ALOX15 (0.54) ALOX15ALDH1A1SMN1; SMN2CYP1A2KDM4E
SCHEMBL30807859 0.88 ALDH1A1 (0.56) ALOX15ALDH1A1SMN1; SMN2CYP1A2KDM4E
SCHEMBL68939 0.88 ALDH1A1 (0.56) ALOX15ALDH1A1SMN1; SMN2CYP1A2KDM4E
SCHEMBL529614 0.87 ALOX15 (0.51) ALOX15ALDH1A1SMN1; SMN2CYP1A2KDM4E
SCHEMBL16688135 0.86 ALOX15 (0.54) ALOX15ALDH1A1SMN1; SMN2CYP1A2KDM4E
SCHEMBL4066413 0.86 ALOX15 (0.54) ALOX15ALDH1A1SMN1; SMN2CYP1A2KDM4E
SCHEMBL3125086 0.86 ALOX15 (0.50) ALOX15ALDH1A1SMN1; SMN2CYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3265447-B1 BENZOXAZINE LOW TEMPERATURE CURABLE COMPOSITION HUNTSMAN ADVANCED MAT AMERICAS LLC (US) 2023-03-01 EP disclosed
US-20180030264-A1 Benzoxazine Low Temperature Curable Composition HUNTSMAN ADVANCED MATERIALS AMERICAS LLC 2018-02-01 US disclosed
EP-3265447-A1 BENZOXAZINE LOW TEMPERATURE CURABLE COMPOSITION Huntsman Advanced Materials Americas LLC (US) 2018-01-10 EP disclosed
EP-0661322-A2 Modified polyepoxy compound, process for producing the compound, and epoxy resin composition SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1995-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030264-A1 Benzoxazine Low Temperature Curable Composition CRYZ, PIEZO1, PSMD12 ALOX15 50/4885ALDH1A1 1543/4885SMN1; SMN2 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.